Allo-Hematopoietic Stem Cell Transplant in China: 2014 Update.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides powerful curative weapons for patients with certain hematological diseases. Great improvements have been made within recent years, particularly in the fields of haploidentical HSCT, allo-HSCT for aplastic anemia, and strategies to overcome relapse and graft versus host disease. This review updates the current state of allo-HSCT in China.
Meng
M
Lv
Xiao-Jun
XJ
Huang
D000741:Anemia, Aplastic / Q000401:mortality / Q000601:surgery*; D002681:China; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality / Q000639:trends; D006648:Histocompatibility; D006801:Humans; D015397:Program Evaluation; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D014019:Tissue Donors / Q000600:supply & distribution; D009927:Tissue and Organ Procurement / Q000458:organization & administration / Q000639:trends; D016896:Treatment Outcome